Adebrelimab plus apatinib and chemo for new bile duct cancer
Part of Cancer, Digestive system clinical trials.
This study tests a combination of three medicines (adebrelimab, apatinib, and standard chemotherapy) for people with newly diagnosed bile duct or gallbladder cancer that cannot be surgically removed. The goal is to see if the combination can shrink the tumor and make it possible to remove later.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with bile duct or gallbladder cancer that has not been treated yet and cannot be removed by surgery.
- You are between 18 and 80 years old.
- You are fully active or able to do light work (ECOG 0-1).
- Your blood counts (white cells, platelets, and hemoglobin) and liver/kidney function are within certain limits.
- You have not had immunotherapy before, do not have an active autoimmune disease, and are not pregnant or nursing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination treatment for biliary tract cancer that is borderline resectable or locally advanced. It combines a chemotherapy infusions directly into the liver (HAIC) with an immunotherapy drug (adebrelimab) and a targeted therapy pill (lenvatinib), aiming to shrink the tumor enough to allow surgery.
This trial tests whether adding adebrelimab to S-1 chemotherapy after surgery helps prevent bile duct cancer from coming back. It may be an option for people who have had their cancer completely removed.
This trial tests a combination of chemotherapy drugs given directly into the liver, combined with two immunotherapy/targeted therapy drugs, for people with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to shrink tumors and improve survival in patients who have not received prior chemotherapy.
This trial tests a combination of immunotherapy (adebrelimab), chemotherapy (gemcitabine and cisplatin), and a cholesterol-lowering drug (simvastatin) for advanced bile duct or gallbladder cancer that cannot be removed by surgery. It aims to see if the addition of simvastatin improves treatment outcomes.
This study tests adding the immunotherapy adebrelimab to standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for advanced biliary tract cancer that can't be removed by surgery. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial tests a combination of four drugs (adebrelimab, apatinib, gemcitabine, and cisplatin) as a first treatment for people with advanced or metastatic bile duct cancer that cannot be removed by surgery. The goal is to see if this combination helps shrink or control the cancer.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.